Here's How Regeneron Plans to Repeat Eylea's Success
Regeneron hopes cholesterol drug alirocumab can diversify its revenue beyond Elyea.
Procter & Gamble Destroyed $4.5 Billion of Investor Value Today -- Should You Care?
Procter & Gamble just dropped $4.5 billion of its market cap and 11 Dow points, but serious investors shouldn't care about either of these figures. There's a better tool.
Amgen Inc's Deep Pipeline Offsets Some of the Price Risk
Amgen's high-quality pipeline offsets some of the sector-wide price risk.
For These 3 Stocks, Recent Weakness Yields Potential Opportunity
These companies reported tough numbers this past quarter. Here's why this may be a great opportunity.
Big Pharma Diversification: A Winning Model or Recipe for Disaster?
Should big pharma companies stick to diversified business models, or should they double down on drug development?